Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. (Q43625314)

25 November 2017

Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. (English)

1 reference

25 November 2017

1 reference

5

Jordan VC

1 reference

25 November 2017

Levenson AS

1

1 reference

25 November 2017

MacGregor Schafer JI

series ordinal

2

1 reference

25 November 2017

Bentrem DJ

series ordinal

3

1 reference

25 November 2017

Pease KM

series ordinal

4

1 reference

25 November 2017

1 January 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

25 November 2017

1 reference

25 November 2017

76

1 reference

25 November 2017

1-5

1 reference

25 November 2017

61-70

1 reference

Clinical potential of new antiestrogens

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Tamoxifen and contralateral breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Molecular mechanisms of resistance to tamoxifen therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Selective oestrogen receptor modulation: molecular pharmacology for the millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Clinical significance of tamoxifen withdrawal response

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Peptide antagonists of the human estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900143-6

7 January 2021

10.1016/S0960-0760(00)00143-6

Identifiers

DOI

1 reference

25 November 2017

1 reference